Exisulind

Peta Jejaring Molekuler

Obat Target Gen Interaksi Enzim Transporter Carrier

Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

1. Pendahuluan & Konsep

Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).

2. Sumber Data (Validasi)

Data Obat: Diekstraksi dari elemen drugbank-id dan name pada skema XML DrugBank.
Target Protein: Diambil dari elemen targets/target yang memuat polipeptida sasaran.
Genetik: Disinkronisasi dari sub-elemen gene-name dan varian snp-effects.
Genetik: Jumlah titik node dibatasi pada maksimal 10 (Slice=10) interaksi untuk menghindari tumpukan data.

3. Algoritma Visualisasi

Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.

4. Legenda Visual

Obat Utama (Pusat Analisis)

Target Protein (Mekanisme)

Gen (Faktor Genetik)

Metode ini mendukung analisis Precision Medicine dan evaluasi risiko Drug-Drug Interaction (DDI).

Profil Farmakokinetik

Waktu Paruh (Half-Life) -

Volume Distribusi -

Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

39 Data

Darbepoetin alfa	The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Exisulind.
Erythropoietin	The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Exisulind.
Peginesatide	The risk or severity of Thrombosis can be increased when Peginesatide is combined with Exisulind.
Methoxy polyethylene glycol-epoetin beta	The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Exisulind.
Lidocaine	The risk or severity of methemoglobinemia can be increased when Exisulind is combined with Lidocaine.
Ropivacaine	The risk or severity of methemoglobinemia can be increased when Exisulind is combined with Ropivacaine.
Bupivacaine	The risk or severity of methemoglobinemia can be increased when Exisulind is combined with Bupivacaine.
Cinchocaine	The risk or severity of methemoglobinemia can be increased when Exisulind is combined with Cinchocaine.
Dyclonine	The risk or severity of methemoglobinemia can be increased when Exisulind is combined with Dyclonine.
Procaine	The risk or severity of methemoglobinemia can be increased when Exisulind is combined with Procaine.
Prilocaine	The risk or severity of methemoglobinemia can be increased when Exisulind is combined with Prilocaine.
Proparacaine	The risk or severity of methemoglobinemia can be increased when Exisulind is combined with Proparacaine.
Meloxicam	The risk or severity of methemoglobinemia can be increased when Exisulind is combined with Meloxicam.
Oxybuprocaine	The risk or severity of methemoglobinemia can be increased when Exisulind is combined with Oxybuprocaine.
Cocaine	The risk or severity of methemoglobinemia can be increased when Exisulind is combined with Cocaine.
Mepivacaine	The risk or severity of methemoglobinemia can be increased when Exisulind is combined with Mepivacaine.
Levobupivacaine	The risk or severity of methemoglobinemia can be increased when Exisulind is combined with Levobupivacaine.
Diphenhydramine	The risk or severity of methemoglobinemia can be increased when Exisulind is combined with Diphenhydramine.
Benzocaine	The risk or severity of methemoglobinemia can be increased when Exisulind is combined with Benzocaine.
Chloroprocaine	The risk or severity of methemoglobinemia can be increased when Exisulind is combined with Chloroprocaine.
Phenol	The risk or severity of methemoglobinemia can be increased when Exisulind is combined with Phenol.
Tetrodotoxin	The risk or severity of methemoglobinemia can be increased when Exisulind is combined with Tetrodotoxin.
Benzyl alcohol	The risk or severity of methemoglobinemia can be increased when Exisulind is combined with Benzyl alcohol.
Capsaicin	The risk or severity of methemoglobinemia can be increased when Exisulind is combined with Capsaicin.
Etidocaine	The risk or severity of methemoglobinemia can be increased when Exisulind is combined with Etidocaine.
Articaine	The risk or severity of methemoglobinemia can be increased when Exisulind is combined with Articaine.
Tetracaine	The risk or severity of methemoglobinemia can be increased when Exisulind is combined with Tetracaine.
Propoxycaine	The risk or severity of methemoglobinemia can be increased when Exisulind is combined with Propoxycaine.
Pramocaine	The risk or severity of methemoglobinemia can be increased when Exisulind is combined with Pramocaine.
Butamben	The risk or severity of methemoglobinemia can be increased when Exisulind is combined with Butamben.
Butacaine	The risk or severity of methemoglobinemia can be increased when Exisulind is combined with Butacaine.
Oxetacaine	The risk or severity of methemoglobinemia can be increased when Exisulind is combined with Oxetacaine.
Ethyl chloride	The risk or severity of methemoglobinemia can be increased when Exisulind is combined with Ethyl chloride.
Butanilicaine	The risk or severity of methemoglobinemia can be increased when Exisulind is combined with Butanilicaine.
Metabutethamine	The risk or severity of methemoglobinemia can be increased when Exisulind is combined with Metabutethamine.
Quinisocaine	The risk or severity of methemoglobinemia can be increased when Exisulind is combined with Quinisocaine.
Nelarabine	The risk or severity of adverse effects can be increased when Nelarabine is combined with Exisulind.
Ambroxol	The risk or severity of methemoglobinemia can be increased when Exisulind is combined with Ambroxol.
Etrasimod	The risk or severity of immunosuppression can be increased when Exisulind is combined with Etrasimod.

Target Protein

cGMP-specific 3',5'-cyclic phosphodiesterase PDE5A

Glutathione S-transferase P GSTP1

Aldo-keto reductase family 1 member B1 AKR1B1

Aldo-keto reductase family 1 member B10 AKR1B10

3',5'-cyclic-AMP phosphodiesterase 4D PDE4D

3',5'-cyclic-AMP phosphodiesterase 4C PDE4C

cGMP-dependent 3',5'-cyclic phosphodiesterase PDE2A

Referensi & Sumber

Artikel (PubMed)

PMID: 15230629
Authors unspecified: Exisulind: Aptosyn, FGN 1, Prevatac, sulindac sulfone. Drugs R D. 2004;5(4):220-6.
PMID: 11358813
Piazza GA, Thompson WJ, Pamukcu R, Alila HW, Whitehead CM, Liu L, Fetter JR, Gresh WE Jr, Klein-Szanto AJ, Farnell DR, Eto I, Grubbs CJ: Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Cancer Res. 2001 May 15;61(10):3961-8.
PMID: 10910034
Thompson WJ, Piazza GA, Li H, Liu L, Fetter J, Zhu B, Sperl G, Ahnen D, Pamukcu R: Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000 Jul 1;60(13):3338-42.

Contoh Produk & Brand

Produk: 0 • International brands: 2

International Brands

Aptosyn — OSI Pharmaceuticals Inc.
Prevatec — Cell Pathways Inc.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.

Deskripsi

Struktur Molekul 2D

Deskripsi metode visualisasi